Evelo Biosciences Inc.

Evelo Biosciences Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Evelo Biosciences Inc. is not a good value stock. Evelo Biosciences Inc. is not very popular among insiders. Evelo Biosciences Inc. is a mediocre stock to choose.
Log in to see more information.
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal mic...

News

Investors Buy Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO)
Investors Buy Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO)

Ticker Report Evelo Biosciences, Inc. (NASDAQ:EVLO Get Free Report) was the target of some unusual options trading activity on Wednesday. Investors acquired 1,885 put options on the company. This...\n more…

Alphabet Inc. Sells 1,007,471 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)
Alphabet Inc. Sells 1,007,471 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)

Ticker Report Alphabet Inc. decreased its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO Free Report) by 95.0% in the 2nd quarter, according to the company in its most recent disclosure with...\n more…

Alphabet Inc. Sells 1,007,471 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)
Alphabet Inc. Sells 1,007,471 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)

Ticker Report Alphabet Inc. decreased its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO Free Report) by 95.0% in the 2nd quarter, according to the company in its most recent disclosure with...\n more…

Evelo Biosciences Sees Unusually Large Options Volume (NASDAQ:EVLO)
Evelo Biosciences Sees Unusually Large Options Volume (NASDAQ:EVLO)

Zolmax Evelo Biosciences, Inc. (NASDAQ:EVLO Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock traders acquired 1,885 put options on the company. This is an...\n more…

Evelo Biosciences cut to Market Perform at TD Cowen after phase 2 EDP2939 data
Evelo Biosciences cut to Market Perform at TD Cowen after phase 2 EDP2939 data

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Evelo Biosciences downgraded to Market Perform from Outperform at TD Cowen
Evelo Biosciences downgraded to Market Perform from Outperform at TD Cowen

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…